

1 Long non-coding RNAs defining major 2 subtypes of B cell precursor acute 3 lymphoblastic leukemia

4 Alva Rani James^{1,2,3}, Michael P Schroeder¹, Martin Neumann^{1,2,3}, Lorenz Bastian^{1,2,3}, Cornelia Eckert^{2,3,4}, Nicola
5 Gökbuget^{2,3,5}, Jutta Ortiz Sanchez¹, Cornelia Schlee¹, Konstandina Isaakidis¹, Stefan Schwartz¹, Thomas
6 Burmeister⁶, Arend von Stackelberg^{2,3,4}, Michael A Rieger^{2,3,5}, Stefanie Göllner⁷, Martin Horstman⁸, Martin
7 Schrappe⁹, Renate Kirschner-Schwabe^{2,3,4}, Monika Brüggemann¹⁰, Carsten Müller-Tidow⁷, Hubert Serve^{2,3,5},
8 Altuna Akalin¹¹, Claudia D Baldus^{1,2,3*}

- 9
- 10 1. Charité, University Hospital Berlin, Department of Hematology and Oncology, Campus Benjamin
- 11 Franklin, Berlin, 12203, Germany
- 12 2. German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
- 13 3. German Cancer Consortium (DKTK), Heidelberg, 69120, Germany
- 14 4. Charité, University Hospital Berlin, Department of Pediatric Hematology/Oncology, Campus Rudolf
- 15 Virchow, 13353, Berlin, Germany
- 16 5. Goethe University Hospital, Department of Medicine II, Department of Hematology/Oncology,
- 17 Frankfurt/M, 60590, Germany
- 18 6. Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Department. of Hematology,
- 19 Oncology and Tumor Immunology, Berlin, 13353, Germany
- 20 7. University Clinic Heidelberg, Department of Hematology, Oncology & Rheumatology, Heidelberg,
- 21 69120, Germany
- 22 8. Research Institute Children's Cancer Center, Department of Pediatric Hematology and Oncology,
- 23 University Medical Center Hamburg, Hamburg, 20251, Germany
- 24 9. University Hospital Schleswig-Holstein, Campus Kiel, Department of Pediatrics, Kiel, 24105,
- 25 Germany.
- 26 10. University Hospital Schleswig-Holstein, Campus Kiel, Department of Hematology and Oncology, Kiel,
- 27 24105, Germany
- 28 11. Bioinformatics platform, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center
- 29 (MDC), Berlin, 13125, Germany

30 *Corresponding author

31 Email: claudia.baldus@charite.de (CDB)

32

33 Abstract

34 Recent studies implicated that long non-coding RNAs (lncRNAs) may play a role in the
 35 progression and development of acute lymphoblastic leukemia, however, this role is not yet
 36 clear. In order to unravel the role of lncRNAs associated with B-cell precursor Acute
 37 Lymphoblastic Leukemia (BCP-ALL) subtypes, we performed transcriptome sequencing and
 38 DNA methylation array across 82 BCP-ALL samples from three molecular subtypes (DUX4,
 39 Ph-like, and Near Haploid or High Hyperdiploidy). Unsupervised clustering of BCP-ALL
 40 samples on the basis of their lncRNAs on transcriptome and DNA methylation profiles
 41 revealed robust clusters separating three molecular subtypes. Using extensive
 42 computational analysis, we developed a comprehensive catalog of 1235 aberrantly
 43 dysregulated BCP-ALL subtype-specific lncRNAs with altered expression and methylation
 44 patterns from three subtypes of BCP-ALL. By analyzing the co-expression of subtype-specific
 45 lncRNAs and protein-coding genes, we inferred key molecular processes in BCP-ALL
 46 subtypes. A strong correlation was identified between the DUX4 specific lncRNAs and
 47 activation of TGF- β and Hippo signaling pathways. Similarly, Ph-like specific lncRNAs were
 48 correlated with genes involved in activation of PI3K-AKT, mTOR, and JAK-STAT signaling
 49 pathways. Interestingly, the relapse-specific differentially expressed lncRNAs correlated
 50 with the activation of metabolic and signaling pathways. Finally, we showed a set of
 51 epigenetically altered lncRNAs facilitating the expression of tumor genes located at their *cis*
 52 location. Overall, our study provides a comprehensive set of novel subtype and relapse-
 53 specific lncRNAs in BCP-ALL. Our findings suggest a wide range of molecular pathways are
 54 associated with lncRNAs in BCP-ALL subtypes and provide a foundation for functional
 55 investigations that could lead to new therapeutic approaches.

56 **Author Summary**

57 Acute lymphoblastic leukemia is a heterogeneous blood cancer, with multiple molecular
 58 subtypes, and with high relapse rate. We are far from the complete understanding of the
 59 rationale behind these subtypes and high relapse rate. Long non-coding (lncRNAs) has
 60 emerged as a novel class of RNA due to its diverse mechanism in cancer development and
 61 progression. lncRNAs does not code for proteins and represent around 70% of human
 62 transcripts. Recently, there are a number of studies used lncRNAs expression profile in the
 63 classification of various cancers subtypes and displayed their correlation with genomic,
 64 epigenetic, pathological and clinical features in diverse cancers. Therefore, lncRNAs can
 65 account for heterogeneity and has independent prognostic value in various cancer subtypes.
 66 However, lncRNAs defining the molecular subtypes of BCP-ALL are not portrayed yet. Here,
 67 we describe a set of relapse and subtype-specific lncRNAs from three major BCP-ALL
 68 subtypes and define their potential functions and epigenetic regulation. Our data uncover
 69 the diverse mechanism of action of lncRNAs in BCP-ALL subtypes defining how lncRNAs are
 70 involved in the pathogenesis of disease and the relevance in the stratification of BCP-ALL
 71 subtypes.

72 INTRODUCTION

73 B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most prevalent disease in
 74 children and affects also adults. Despite improvements in treatment regimens such as
 75 chemotherapy and allogeneic hematopoietic stem cell transplantation, the prognosis
 76 remains poor for patients in high-risk groups and at relapse (1). Various risk subtypes have
 77 been established based on the cytogenetic analysis and molecular genetics studies. These
 78 subtypes are classified based on the presence of high hyperdiploidy (51-65 chromosomes)
 79 (2), hypodiploidy (less than 44 chromosomes)(3) and fusion genes (for example BCR-ABL,
 80 ETV6-RUNX, MLL, etc)(4). About 70-80% of both adults and pediatric cases of BCP-ALL
 81 constitute these subtypes, although the frequency may differ (5).

82 Recent efforts taking advantage of whole transcriptome sequencing (RNA-Seq) have refined
 83 this classification by identifying novel BCP-ALL subtypes. RNA-Seq analysis identified
 84 cytogenetically non-detectable recurrent rearrangements and gene fusions, which allowed
 85 characterization of additional subtypes based on distinct gene expression profiles (6). For
 86 example, the DUX4 (7) subtype is defined mainly by the IGH-DUX4 or ERG-DUX4 gene
 87 fusions; the Ph-like (8) subtype is a high-risk subtype with a gene expression profile similar
 88 to Ph-positive ALL; however, lacking BCR-ABL1 fusion gene; and the Near Haploid/High
 89 Hyperdiploid (NH-HeH) (51–67 chromosomes) subtype (9,10) is a common subtype,
 90 comprising 30% of all pediatric BCP-ALL. These subtypes are clinically relevant with
 91 distinct gene expression profile and have been widely studied in the recent past.
 92 Nevertheless, we are far from complete understanding of BCP-ALL subtypes and their
 93 heterogeneity and its associated molecular mechanisms, which pose a major challenge for
 94 improving diagnosis and therapy. Recent studies have suggested that long non-coding RNAs
 95 (lncRNAs) and small non-coding RNAs (e.g. microRNAs) might play a key role in

development and progression of leukemia (11) and thus constitute as new biomarkers and potential targets for novel therapies (12).

LncRNAs are arbitrarily defined as transcripts longer than 200 base pairs and lacking an extended protein-coding open reading frame (ORF). It has become apparent that lncRNAs are frequently spliced and polyadenylated and are mainly transcribed by RNA polymerase II (13). LncRNAs expression has been reported as highly tissue-specific even though the expression abundance is generally lower compared to protein-coding genes (14). The expression specificity has been extended to a wide variety of physiological and pathological mechanisms like cancer development and Pluripotency (15). LncRNAs can act either proximally (in the cis region) or distally (in the trans region) for the transcriptional regulation of protein-coding genes (16). Like proteins, various lncRNAs are attributed to oncogenic or tumor-suppressive (17) activities exerting various cellular functions (18). In addition, lncRNAs regulate gene expression at the epigenetic (19) and post-transcription (20) levels. Genome-wide association studies in cancer have disclosed that 80% of cancer-associated single-nucleotide polymorphisms (SNPs) are in non-coding regions (21), including lncRNAs, suggesting that a significant portion of the genetic etiology of cancer can be related to lncRNAs (22). Moreover, lncRNAs are reported to be useful for disease prognosis, exemplified by the lncRNA HOTAIR (HOX transcript antisense RNA), which is up-regulated in acute myeloid leukemia (AML) patients (23). So far, the majority of studies explored the role of single lncRNAs in leukemia including AML (24), chronic lymphocytic leukemia (CLL) (25) and pediatric ALL (26). Yet a comprehensive genomic and epigenetic delineation of lncRNAs deregulations in BCP-ALL subtypes, and their molecular and functional insights are lacking.

In the present study, we explored lncRNA landscapes in DUX4, Ph-like, and NH-HeH BCP-

ALL subtypes and extracted novel biological and functional insights of BCP-ALL subtype-specific lncRNAs and their epigenetic activity. On the basis of RNA-seq transcriptional and DNA methylation survey of lncRNAs, we have determined 1235 subtype-specific, relapse-specific markers and epigenetically altered lncRNAs and demonstrated their relevance in BCP-ALL subtype classification. From our in-depth analyses, we have inferred the potential functions of subtype-specific lncRNAs. Overall, this work provides a most comprehensive and integrative resource which highlights the impact of lncRNAs on relevant pathways that are dysregulated in the molecular subgroups of BCP-ALL and may provide new approaches for prognosis and treatment.

RESULTS

Unique lncRNAs expression profiles characterize BCP-ALL subtypes

To identify BCP-ALL subtype-specific lncRNAs, we analysed transcriptome profiles from paired initial diagnosis (ID) and relapse (REL) samples of 26 pediatric and 22 adult BCP-ALL patients lacking known chromosomal translocations like BCR-ABL. Based on DNA mutations and chromosomal translocations combined with RNA expression and DNA methylation profiles the samples were classified into different molecular subtypes (Table S1), namely DUX4 (n = 23), Ph-like (n = 21), Near Haploid or High Hyperdiploid (NH-HeH) (n = 16), and low-hypodiploid (LH) (n = 6) and others (n = 18).

When the distribution of lncRNAs gene expression levels across all BCP-ALL samples was compared with that of protein-coding genes, the former generally showed lower expression levels than the latter (27) (Fig S1A, Table S1). The principal component analysis (PCA) on the expression (FPKM value) of 13,860 GENCODE lncRNAs revealed three major BCP-ALL subtypes, DUX4, Ph-like and NH-HeH with a distinct separation (Fig 1A). This observation is in concordance to the predefined molecular classification. In particular, samples of the

144 DUX4 subtype showed robust separation compared to the remaining samples implying a
145 subtype-specific lncRNAs signatures.

146 To unveil differentially expressed (DE) lncRNAs across these three major molecular
147 subtypes, we performed DE analysis between subtypes. We obtained 1235 significant DE
148 subtype-specific lncRNAs (P -value ≤ 0.01 and absolute Fold change $\geq \pm 1.5$) defining
149 signatures of three subtypes (Fig 1B, Fig S2A-C, Table S1). Of these, 24 lncRNAs were
150 commonly detected in all 3 BCP-ALL subtypes (Fig 1C), about 523 (Hypergeometric P -value
151 $= 9.2E-29$) subtype-specific lncRNAs overlapped with deregulated lncRNAs from 12 other
152 cancer types (Fig S2D, Table S1) (28). The remaining 46% ($n = 713$) of BCP-ALL subtype-
153 specific DE lncRNAs were novel and specific to our subtypes. Out of the overlapped DE
154 lncRNAs ($n = 523$), 23 (Table S1) were cross-validated in independent cohorts from
155 lnc2cancer (29) database and found to be enriched for oncogenic class of lncRNAs. For
156 example, oncogenic lncRNAs *PVT1* (30) and *GAS5* (31) are differentially up-regulated in
157 the DUX4 subgroup, and *CRNDE* (32) is DE in Ph-like subgroup. Together, subtype-specific
158 lncRNAs signatures assigned molecular subgroups of BCP-ALL.

159 **Identification and inferred functions of lncRNAs associated with molecular subtypes** 160 **of BCP-ALL**

161 As lncRNAs can function by regulating protein-coding genes in *cis* and/or *trans* (33–36)
162 regions, we performed functional enrichment analyses using guilt-by-association approach
163 based on the correlation between neighbouring (*cis*) and distally (*trans*) located protein-
164 coding (PC) genes (within ± 100 kb *cis* and $> \pm 100$ kb window for *trans*) of the subtype-
165 specific lncRNAs (see materials and methods). Expression of both *cis* and *trans* PC genes
166 showed a higher tendency towards positive correlation with the expression of the
167 corresponding lncRNAs (Table 1).

Table 1: Number of BCP-ALL subtype-specific lncRNAs co-expressed with its *cis* and *trans* PC genes.

Subtypes	<i>Cis</i> PC genes (n = 929)	<i>Cis</i> co-expressed DE lncRNAs (n = 62)	<i>Trans</i> PC genes (n = 753)	<i>Trans</i> co-expressed DE lncRNAs (n = 552)
Ph-like	260	170 (383)	261	173 (383)
DUX4	669	451 (736)	492	379 (736)

The table represents the number of DE lncRNAs showed *cis* (≤ 100 Kb proximity) and *trans* (≥ 100 Kb) protein coding genes and the number of DE lncRNAs co-expressed with them. The numbers shown within the bracket is the total number of DE lncRNAs corresponding to the respective subtypes.

Significantly co-expressed (Pearson correlation coefficient ≥ 0.55 , 2-tailed *P*-value ≤ 0.05) *cis* and *trans* protein-coding genes associated with DUX4 (n = 58 in *cis* and n = 127 in *trans*) and Ph-like (n = 24 in *cis* and n = 20 in *trans*) specific DE lncRNAs demonstrated activation of key signalling pathways involved in proliferation, apoptosis, and differentiation in leukemia (Table S2). For example, in the *cis* based analysis, we identified a strong correlation between DUX4 specific lncRNAs and genes involved in the TGF-beta, Hippo, and P53 signalling pathways (Fig 2A, Table S2). Whereas, the Ph-like specific lncRNAs were correlated with genes involved in JAK-STAT, mTOR, and PIK3-AKT signalling pathways (Fig 2B, Table S2). The *trans* based analysis revealed same vital signalling pathways in DUX4 subtype (Fig S3A-B, Table S2), whereas in Ph-like subtype we identified additional signalling pathways, including, P53 and mitogen-activated protein kinase (MAPK) pathways (Fig S3C, Table S2). The strongly co-expressed *cis* PC genes with DE lncRNAs (n = 32) includes oncogenes including, *IL2RA* (37), *TGFB2* (38), and *CDK6* (39) activated in signalling pathways from DUX4 and Ph-like subgroups (Fig S4A-D, Table 2-3).

189 **Table 2. Subtype-specific lncRNAs and oncogenes.**

Subtype-specific lncRNAs	Pearson correlation coefficient	P-value	Oncogene
RP11-347C18.3	0.56	3.25E-008	CDK6
RP11-461F16.3	0.62	5.21E-010	
RP11-96H19.1	0.62	3.89E-010	
RP11-228B15.4	0.64	7.68E-011	
MME-AS1	0.56	3.68E-008	
CTB-39G8.3	0.57	1.78E-008	
AC002454.1	0.72	2.21E-014	
RP11-582J16.4	0.55	8.08E-008	
AC009970.1	0.64	6.23E-011	
RP11-229P13.20	0.66	1.44E-011	
LINC00114	0.57	3.06E-008	
CTB-118N6.3	0.61	9.70E-010	
SOCS2-AS1	0.62	4.94E-010	
CTD-2561B21.10	0.61	9.91E-010	
RP11-413E1.4	0.56	4.36E-008	
KB-1460A1.1	0.55	7.77E-008	
AC012309.5	0.59	4.10E-009	
RP11-37B2.1	0.59	4.76E-009	
ASB16-AS1	0.65	3.86E-011	
LINC00426	0.62	6.32E-010	
LINC01071	0.57	2.46E-008	
RP11-536K7.5	0.74	5.11E-15	IL2RA
RP11-224O19.2	0.98	1.08E-061	TGFB2
AC004837.5	0.83	6.11E-023	
RP11-251M1.1	0.79	7.39E-019	
CTD-2571L23.8	0.75	2.94E-016	
RP11-35O15.1	0.65	3.36E-011	
AC139100.3	0.58	1.00E-008	
RP11-158M2.3	0.58	1.50E-008	
RP11-672A2.5	0.56	4.68E-008	
CTD-2357A8.3	0.55	7.46E-008	
RP11-677M14.3	0.55	6.68E-008	

190 Positively correlating novel *cis* subtype-specific lncRNAs with oncogenes, *CDK6*, *TGFB2*,
191 and *IL2RA* from Ph-like and DUX4 subtypes.

192 **Table 3: Subtype-specific novel DE lncRNAs co-expressed with oncogenes, which are**
193 **associated with vital molecular pathways.**

Subtype-specific lncRNAs	Cis PC	Pearson correlation coefficient	Associated pathways
RP11-224O19.2 AC004837.5 RP11-251M1.1 CTD-2571L23.8	TGFB2	0.98 0.83 0.79 0.75	Hippo TGF- β Endocytosis

AC093818.1 AC078883.3	ITGA6	0.95 0.68	PI3K-Akt
U62631.5	CD22	0.78	Cell adhesion molecules (CAMs) B cell receptor signaling pathway
CTD-2267D19.2 RP11-486L19.2	RARA	0.89 0.70	Pathways in cancer Transcriptional mis-regulation in cancer pathways

The table represents the novel subtype specific DE lncRNAs co-expressed with its *cis* genes such as *TGFB2*, *ITGA6*, *CD22*, and *RARA* genes, which were enriched in vital molecular pathways in BCP-ALL.

However, there were no significant pathways identified within NH-HeH subtype. The subtype-specific *cis* and *trans* acting lncRNAs which are up-regulated and correlated with genes involved in signalling pathways from DUX4 and Ph-like subtypes were hinting their gene expression regulatory activity.

We next related the functions of DUX4 and Ph-like specific DE lncRNAs obtained from *cis* based analysis to those functions identified with DE PC genes. We observed an overlap of 100% (n = 18, Table S2) of pathways from the DUX4 subtype between lncRNAs based and PC based functional enrichment analysis (Fig 2C). Whereas, in Ph-like subtype, we identified 60% (9 out of 15) same pathways between DE PC based and DE lncRNAs based functional enrichment analysis (Table S2 and Fig 2D). However, we identified Ph-like specific lncRNAs to be more strongly correlated with genes involved in key signalling pathways than Ph-like specific protein-coding genes. For example, we identified mTOR and PI3K-AKT exclusively in the Ph-like specific lncRNAs based analysis. Together, our analyses highlight important functions of BCP-ALL subtype-specific lncRNAs whose expression correlates tightly with that of cancer-related oncogenes.

Relapse-specific lncRNAs driving BCP-ALL progression

To gain insights into the possible role of lncRNAs driving BCP-ALL progression, we investigated dysregulation of lncRNAs at relapse. For each molecular BCP-ALL subtype, we

performed a differential expression analysis of lncRNAs between ID and REL samples (Fig 3). 947 lncRNAs (Table S3) emerged as significantly DE (absolute Fold change $\geq +1.5$; P -value ≤ 0.01) between ID and REL from the three subtypes. Around 20% ($n = 186$) of those DE lncRNAs were up-regulated and 80% were down-regulated at relapse. The hierarchical clustering on relapse-specific lncRNAs within each subtype (DUX4, Ph-like, NH-HeH) identified clear separation between ID and REL (Fig 3A-C). We observed 19% (183) relapse-specific lncRNAs identified here overlapped with subtype-specific lncRNAs (Fig 3E). The putative molecular functions of relapse-specific lncRNAs were identified using the previously mentioned guilt-by-association approach. Relapse-specific lncRNAs within Ph-like and NH-HeH subtypes did not show any significant correlation with activation of pathways. In contrast, in the DUX4 subtype, we identified 56% ($n = 321$) relapse-specific lncRNAs correlated with *cis* PC genes (Table S3). These strongly correlated relapse-specific lncRNAs showed activation of PC genes involved in vital signalling pathways and metabolic pathways, including NF-kappa B-signalling pathway, cell adhesions molecule (CAMs) and metabolic pathways (number of genes involved ≥ 3 and P -value ≤ 0.05) (Fig 3D, Table S3). These results indicate that relapse-specific markers from DUX4 subtype may be functionally engaged in metabolic and signalling pathways.

Subtype specific BCP-ALL lncRNAs show epigenetic alterations

For the analysis of the methylation status of loci located at the lncRNAs genomic position in the BCP-ALL subtypes, we used DNA methylation array data (collected from Illumina 450k methylation array) from the same patients ($n = 46$) including matched diagnosis (ID) and relapse (REL) samples ($n = 82$). The distribution of DNA methylation levels of CpG sites ($n = 60,021$, Table S4) associated with 7,160 lncRNAs was compared with CpG sites associated with PC genes across all BCP-ALL samples. Unlike the expression levels, the

distribution of DNA methylation (hypo-methylation or hyper-methylation) between lncRNAs and PC genes were similar (Fig S1B). Given the robust separation of BCP-ALL subtypes on DNA methylation profile of CpGs associated with lncRNAs on the PCA analysis (Fig 4A), we next studied the differential hypo-methylated (methylation difference value < 0 ; P -value ≤ 0.05) and hyper-methylated (methylation difference value > 0.2 ; P -value ≤ 0.05) CpGs associated with lncRNAs in each subtype (see materials and method). The hierarchical clustering of differentially methylated (DM) lncRNAs showed distinct methylation patterns of each subtype, concordant with the DE lncRNAs signature (Fig 4B-D, Table S4). In the DUX4 and NH-HeH subtypes the number of hypo-methylated lncRNAs (differential methylation value < 0 , P -value ≤ 0.05) were higher compared to the number of hyper-methylated lncRNAs. We classified the DM lncRNAs based on their genomic regions as gene body methylated and promoter-TSS methylated. In the promoter methylated lncRNAs we identified the same trend with high degree of hypo-methylated and lower number hyper-methylated lncRNAs in DUX4 and NH-HeH subtypes. However, the Ph-like subtype has shown a higher degree of hyper-methylated DM lncRNAs than hypo-methylated DM lncRNAs. The list of subtype-specific DM lncRNAs from three subtypes contained previously defined epigenetically altered lncRNAs from other cancer types, for example, we observed the oncogenic lncRNAs *LINC00312* (40), *PVT1*, and *TCL6* (41), which are differentially methylated in at least one of the three subtypes. Together, this data illustrates that epigenetically altered lncRNAs within three BCP-ALL subtypes.

260 **Correlation between differentially expressed and differentially methylated lncRNAs**

In order to define whether the subtype-specific promoter methylation impacts on the expression level, we compared the promoter-TSS differential CpG methylated lncRNAs ($n = 227$) with its differential expression signature. We observed 44 lncRNAs with differential

methylation pattern in their promoter region with differential expression pattern at RNA level. Out these, lncRNAs harboring significant hypo-methylation and hyper-methylation pattern (Pearson correlation, 2-tailed P -value ≤ 0.05) at the promoter region accounted for 23 (Table 4) lncRNAs across the three BCP-ALL subtypes.

Table 4: The list of significantly correlated DNA methylation and expression for promoter methylated lncRNAs (n = 23) from BCP-ALL subtypes.

DM lncRNAs	Pearson correlation coefficient	P-value	Methylation	Absolute Fold change	Subtypes
AC003075.4	-0.31	0.004	1.43	-1.26	DUX4
AC099754.1	-0.32	0.002	-1.74	3.2	
AC104655.3	-0.26	0.017	-2.27	2.07	
CACNA1C-AS1	-0.45	2.03E-05	1.97	-1.62	
CTB-25B13.9	-0.26	0.016	-1.73	1.46	
IGF2-AS	-0.24	0.028	-1.33	4.95	
LINC01006	-0.39	0.001	-2.06	2.53	
PVT1	-0.40	0.001	-2.13	1.15	
RGBM-AS1	-0.26	0.0193	-1.48	5.96	
RP11-125B21.2	-0.35	0.001	-1.75	4.11	
RP11-138M12.1	-0.70	5.21E-13	-5.98	3.77	
RP11-367G6.3	-0.30	0.004	1.98	-1.63	
RP11-624M8.1	-0.50	1.34E-06	-3.34	4.13	
RP11-789C17.3	-0.36	0.001	-2.27	3.2	
SERTAD4-AS1	-0.25	0.0232	-1.98	1.79	
LINC01006	-0.38	0.0003	1.44	-1.56	Ph-like
RP11-138M12.1	-0.70	5.21E-13	2.06	-1.44	
RP11-305F18.1	-0.64	5.36E-11	1.76	-2.08	
AC099754.1	-0.33	0.002	1.21	-1.36	
ACVR2B-AS1	-0.36	0.0009	2.18	-1.75	
LINC00996	-0.39	0.0003	-1.56	2.11	
ERICH1-AS1	-0.40	0.0006	-1.82	2.21	
DIO3OS	-0.31	0.0037	-1.76	4.05	NH-HeH
U3	-0.83	1.346E-22	-2.01	2.43	

The lncRNAs are promoter differentially methylated and differentially expressed in their

271 corresponding subtypes. DM: Differentially methylated. The significance is calculated
 272 based on Pearson correlation rate and two -tailed P -value ≤ 0.05 .

273 Of these 23 putative epigenetically facilitated lncRNAs, 15 were related to the DUX4
 274 subgroup (Fig 5A) including the novel lncRNAs, *R11-138M12.1* and *RP11-624M8.1*. These
 275 were significantly hypo-methylated at their promoter region and transcriptionally up-
 276 regulated in the DUX4 subgroup (Pearson correlation coefficient = -0.69; P -value = 5.1E-
 277 13 for *R11-138M12.1*; Pearson correlation coefficient = -0.50; P -value = 1.36E-06 for
 278 *RP11-624M8.1*; Fig 5B and 5C). In the Ph-like subtype, we observed 7 lncRNAs with
 279 promoter methylation (Fig 5D); interestingly, the same lncRNA *R11-138M12.1* showed
 280 significant hypermethylation at the promoter region and a concordant down-regulation in
 281 the Ph-like subgroup (Fig 5E). Besides these novel lncRNAs, we identified lncRNAs
 282 previously reported in the context of different cancers from our epigenetically altered
 283 results. The lncRNAs *PVT1* (Pearson correlation coefficient = -0.40, 2-tailed P -value \leq
 284 0.001), and *DIO3OS* (42) (Pearson correlation coefficient = -0.31, 2-tailed P -value =
 285 0.0037) are examples, which we observed in the DUX4 and NH-HeH subtype with
 286 significant anti-correlation (2-tailed P -value ≤ 0.01) to its expression level. Around 46%
 287 ($n = 512$) of DM subtype-specific lncRNAs are localized in the intronic and intergenic
 288 genomic regions. We next aimed to investigate whether these lncRNAs regions has
 289 chromatin markers encoded within their genomic location. Recent human genome-wide
 290 chromatin marker study (43) has provided us with a rich resource to identify chromatin
 291 markers. Genome-wide mapping of B-lymphocyte cell line by searching for epigenetic
 292 markers within our DM subtype-specific intronic and intergenic regions revealed a
 293 significant number of lncRNAs ($n=53$) (Table S4, Fisher exact test P -value = 2.2E-16)
 294 with enhancer and insulator markers (Table S4). Out of these, lncRNAs, *RP11-134O21.1*,

295 *RP11-398B16.2*, *RP11-689B22.2*, *CTC-458I2.2* and *LINC00880* were DE expressed, with a
296 significant negative correlation between DNA methylation and expression levels in the
297 DUX4 subtype (Table 5) .

298 **Table 5: The list of significantly correlated DNA methylation and expression for**
299 **intronic and Intergenic methylated lncRNAs (n = 5) from DUX4 BCP-ALL subtypes.**

DM lncRNAs	Absolute Fold change	Methylation value	Pearson correlation rate	P-value	Epi-markers	Biotype
RP11-134O21.1	2.54	-1.56	-0.63	1.9E-010	Enhancer	Intron
RP11-398B16.2	2.08	-1.85	-0.47	0.0007	Insulator	
RP11-689B22.2	1.52	-3.37	-0.47	0.008	Enhancer	
CTC-458I2.2	-1.16	3.38	-0.42	0.0001	Enhancer	
LINC00880	-1.45	2.23	-0.25	0.02	Enhancer	Intergenic

300 The significance is calculated based on Pearson correlation rate and two -tailed *P*-value
301 ≤ 0.05 . The lncRNAs are promoter differentially methylated and differentially
302 expressed in their corresponding subtypes. These lncRNAs are with enhancer and
303 insulator epigenetic markers. DM: Differentially methylated.

304 These findings suggest that epigenetic silencing and activation of promoter lncRNAs may be
305 a mechanism that contributes to the dysregulation of expression of lncRNAs. In addition to
306 that, both intronic and intergenic DM lncRNAs associated with strong enhancer and
307 insulator regions can accelerate its expression at the epigenetic level.

308 **Epigenetic alterations of subtype-specific lncRNAs are associated with elevated**
309 **expression of tumor genes located at their *cis* region**

310 We next investigated the relationship between the epigenetic alterations of DM subtype-
311 specific lncRNAs (n = 1118) and the aberrant expressions of their *cis* PC genes. We found

78 protein-coding genes located in their *cis* region, out of these 33 protein-coding genes have shown a significant up-regulated and down-regulated expression pattern in their corresponding subtypes (Table 6).

Table 6: The list of DNA methylated lncRNAs and differentially up and down-regulated *cis* PC genes from three subtypes.

Subtype-specific Methylated lncRNAs	DNA methylation	Cis PC	Absolute Fold change	Subtype
CTD-2231H16.1	-1.6803385981	PLEKHG4B	2.4840131576	DUX4
RP11-80H8.4	-4.8712973818	CHST2	5.021248353	
IGF2-AS	-1.5149692084	IGF2	6.7074586227	
RP11-332H18.4	1.7840373497	TBX2	5.6459057649	
RP11-332H18.4	1.7840373497	TBX4	1.5056957579	
RP11-624M8.1	-3.3400278742	HEY2	3.5653881965	
CTB-25B13.9	-1.7341024339	REEP6	1.0135168425	
RGMB-AS1	-1.4711332705	RGMB	4.4287098777	
AC073316.1	-2.1346425435	SDK1	4.2539854375	
CTB-35F21.2	-3.3996007483	CXXC5	1.5322350503	
CTB-35F21.2	-3.5262894443	PSD2	2.0348265047	
AC099754.1	-1.7432607805	LRRC3B	3.2956570803	
AC078883.4	-3.4089445499	CORO1C	0.797282079	
AC078883.4	-3.4089445499	ITGA6	3.2489394471	
RP11-314O13.1	-1.5432811428	CDYL2	1.7070802978	
RP3-455J7.4	-3.0695619042	CREG1	1.5618184051	
RP11-125B21.2	-1.749750681	VLDLR	4.2858349208	
RP11-676J12.8	-1.8927665898	GLOD4	0.6471353534	
LINC00114	3.4320004844	ETS2	-0.7176247124	
RP11-367G6.3	1.9798401851	THBS4	-1.5796823436	
CTC-458I2.2	3.3822300323	CTGF	-1.892559675	
RP11-69I8.3	2.355315514	AHR	-2.4815111685	
RP11-293A21.1	-3.6963992484	STIM2	2.487452138	NH-HeH
LINC00114	-2.9731205546	ETS2	0.9908037963	
ACVR2B-AS1	2.3094716973	ACVR2B	-2.4697071313	Ph-like
AGAP1-IT1	2.0926102582	AGAP1	-2.9857451706	
RP11-69I8.3	-3.1689478827	CTGF	1.8492946882	
LINC00996	-1.553999019	GIMAP8	1.4145369937	
AC099754.1	1.2121139088	LRRC3B	-2.0406367867	

CTB-79E8.2	-2.2285747372	NEURL1B	1.1469246971	
AL133493.2	2.0838061516	PCBP3	-3.0795988736	
RP11-420G6.4	-2.4300037457	SERPINB1	0.5848645847	

The table represents hypo-methylated and hyper methylated lncRNAs from three subtypes elevating and diminishing the expression of the protein-coding genes localized at their cis regions. The PC genes differentially up and down regulated in the respective subtypes include tumor genes as well. The highlighted rows are some examples of oncogenes with up-regulated expression profile within DUX4 subtype.

Intriguingly, the up-regulated PC genes include known tumor genes from various cancer types. For example, *IGF2* (44) (absolute fold change = 6.70, *adj.P-value* = 0.0061), *CTGF* (45) (absolute fold change = 1.85, *adj.P-value* = 0.02) and *ETS2* (46) (absolute fold change = 0.99, *adj.P-value* = 0.01) from DUX4, Ph-like and NH-HeH subtypes respectively (Fig 6 A-C). Together, this illustrates a set of lncRNAs which are capable of epigenetically elevating and silencing the expression profile of tumor genes localized in its *cis* region in BCP-ALL subtypes.

DISCUSSION

Although previous studies have demonstrated the involvement of lncRNAs in acute leukemias (25,26) comprehensive characterization of the transcriptome, epigenetic regulation and functional contribution of lncRNAs in distinct BCP-ALL subtypes are lacking. lncRNAs, as the novel class of functional molecules involved in cancer biology, is defined in the stratification of different molecular subtypes in various cancers (47–49). However, their role in BCP-ALL subtypes has not been investigated. Here, we unravel the lncRNAs landscape using transcriptome and methylome data from 46 (adult and pediatric) relapsed BCP-ALL patients focusing on the three molecular subtypes namely, DUX4, Ph-like, and NH-HeH. Our integrated transcriptomic analyses using RNA-seq and DNA methylation brings

339 significant insights and advances over other studies: it provides the most comprehensive
 340 novel datasets so far for BCP-ALL subtypes, a resource of subtype-specific and relapse-
 341 specific lncRNAs, potential lncRNAs functions and uncovers their epigenetic alterations of
 342 the BCP-ALL subtypes. We identified 1235 DE subtype-specific lncRNAs dysregulated in at
 343 least one of the three subtypes. Compared to the pan-cancer comprehensive set of
 344 aberrantly expressed lncRNAs we found 66% (712 out of 1564) of our DE lncRNAs were
 345 more specific for our subtypes introducing novel insight in the non-protein-coding part of
 346 the genome in BCP-ALL subtypes.

347 Another important aspect of our study is the identification of relapse-specific dysregulated
 348 lncRNAs across three BCP-ALL subtypes. A closer look into the relapse-specific lncRNAs
 349 signature identified lncRNAs previously described as oncogenic: lncRNAs including, *RP11-*
 350 *701P16.5* (50), *SLC38A3* (51), and *LINC00312* (40), which are up-regulated in relapsed
 351 samples within DUX4 subtype (Table 7).

352 **Table 7: Previously reported lncRNAs identified as relapse-specific lncRNAs in BCP-**
 353 **ALL subtypes.**

Relapse-specific lncRNAs	Disease association
TCL6 (DUX4)	Chromosomal translocations T-cell leukaemia/lymphoma (2)
LINC00312 (DUX4, Ph-like, NH-HeH)	Proliferation, invasion, and migration of thyroid cancer, Nasopharyngeal carcinoma (3)
miR-17-92a-1 (DUX4, Ph-like, NH-HeH)	Development, progression, and aggressiveness of colorectal cancer (4)

354 The differentially expressed lncRNAs between relapse (REL) and initial diagnosis
 355 (ID), from three subtypes, which were previously reported for its disease association,
 356 selected representative examples from relapse-specific lncRNAs, which are previously
 357 identified in other diseases.

358 Importantly, apoptosis suppressor lncRNA in myc-driven lymphomas (52) *miR-17/92*
359 cluster host gene (*MIR17HG*) is up-regulated in relapse samples within the Ph-like subtype
360 and down regulated in relapsed samples within DUX4 and NH-HeH subtypes. Overall, the
361 relapse-specific lncRNAs highlights the oncogenic relevance in BCP-ALL subtypes.

362 Besides the oncogenic properties, lncRNAs can act as prognostic markers (53) and aid for
363 disease diagnosis and treatment. A subset of our relapse-specific lncRNAs (n = 61, Table
364 S3) is recently identified as prognostic markers in 14 Pan-Cancer data (36) types, including
365 Lung Cancer Associated Transcript 1 (*LUCAT1*), which is previously reported for its drug
366 resistance in solid cancer (54). Within the DUX4 subtype, we identified up-regulated
367 expression of *LUCAT1* at relapse, potentially providing a novel insight into treatment
368 resistance for BCP-ALL subtypes. Together, this illustrates the catalog of relevant lncRNAs
369 in different subtypes of BCP-ALL as subtype-specific and relapse-specific markers with the
370 potential of RNA based treatments in the treatment of BCP-ALL subtypes.

371 The dissection of the regulatory pathways mediated by the molecular subtype-specific and
372 relapse-specific lncRNAs revealed the activation of pivotal signalling pathways across three
373 BCP-ALL subtypes. The functional analysis using guilt-by-association approach highlights
374 the subtype-specific and relapse-specific lncRNAs associated with activation of signaling
375 pathways and metabolic pathways that are associated with leukemogenesis including TGF-
376 Beta, hippo, P53, and JAK-STAT, cytokine-cytokine receptor, endocytosis, mTOR and
377 metabolic pathways. Characterization of the lncRNAs involved in this pathway may
378 potentially reveal novel targets in molecular therapies.

379 The functional insights of relapse-specific and subtype-specific lncRNAs revealed biological
380 relevance to BCP-ALL subtypes including cell cycle functions, signal transduction, cell
381 migration and metabolic processes. Some of the functions predicted here corroborate

previous studies emphasizing the strengths of the employed guilt-by-association. For example, lncRNA *AC002454.1*, which we associated to the PIK3-AKT pathway in Ph-like subtype, was recently reported to regulate cyclin-dependent kinase (*CDK6*) to participate in cell cycle disorder (55). The *CDK6* gene appears to be frequently dysregulated in hematopoietic malignancies (39) and is hence attributed a critical role in tumorigenesis, also shown in ALL driven by mixed lineage leukemia fusion proteins (56). In Ph-like subtype, both *CDK6* and *AC002454.1* are correlated and up-regulated specifically in Ph-like samples, suggesting they displayed enhancer-like functions. We identified 8 relapse-specific lncRNAs (Table S3) associated with metabolic pathways in the DUX4 subtype overlapping with lncRNAs reported (57) to synergistically dysregulate metabolic pathways in multiple tumour context.

Besides known lncRNAs, we also identified novel lncRNAs associated with activation of key signalling pathways. For instance, in DUX4 subtype, we identified a set of novel lncRNAs associated with TGF-beta pathway, including the antisense *RP11-224019.2*, with a significant positive correlation to the *TGFB* gene. Recently, there are a number of lncRNAs documented to be associated with TGF β signalling pathway, including MEG3 regulating the TGFB2 pathway in breast cancer (58). However, lncRNAs associated with the TGF β pathway in BCP-ALL subtypes have not been reported. The co-expression of *RP11-224019.2* and *TGFB* in DUX4 subtype may indicate their functional relatedness or regulatory relationships. In addition to that, a notable observation was a strong correlation between relapse-specific lncRNAs with genes involved in the activation of metabolic pathways in the DUX4 subtype. We identified 112 relapse-specific lncRNAs co-expressed with 29 (Table S3) PC genes activated in metabolic pathways, including previously reported 8 biomarker lncRNAs. For example, we identified oncogenic lncRNA *LUCAT1* reported to be associated

with poor prognosis in lung cancer (54). However, the *LUCAT1* has not yet been reported in the BCP-ALL context. The global co-expression analysis and gene-expression profiling suggest important and previously unappreciated roles of lncRNAs in the BCP-ALL subtypes. Our analyses provide important functions of subtype-specific and relapse-specific lncRNA genes whose expression correlates tightly with oncogenic coding genes. Although we observed that subtype-specific lncRNAs and subtype-specific protein-coding genes were predicted to activate or inhibit the same pathways, some important exclusivity was observed. For instance, the signalling pathways such as the PI3K and mTOR in Ph-like subtype was enriched only in the lncRNAs based enrichment analysis, whereas these pathways did not appear to be enriched/dysregulated in the mRNA based analysis. The PI3K and mTOR signalling pathways control proliferation, differentiation, and survival of hematopoietic cells (59). Consistent with our studies, other studies indicated the potency of lncRNAs facilitating the cancer cell growth through mTOR and PI3K signalling pathways (36,47,60) yet reports on BCP-ALL subtypes are lacking. Considering the functional nexus between Ph-like specific lncRNAs and the activation of pathways such as mTOR and PI3K signalling pathways, targeting those lncRNAs may be a promising novel therapeutic target for BCP-ALL subtypes. Our work additionally underscores the importance of epigenetic alterations in modulating lncRNAs transcriptional activities. Although previous studies (16, 57) have demonstrated cross-talk between DNA methylation and transcriptional activities of lncRNAs, their role in the etiology of BCP-ALL subtypes has not been investigated. DNA methylation analyses of lncRNAs revealed that DNA methylation might underlie the differential expression of BCP-ALL subtype-specific lncRNAs. Subtype-specific lncRNAs identified here have been reported by previous studies. For example, *SOX2-OT* (62), *LINC00312* (63), *TCL6* and *PVT1*, are

430 onco-lncRNAs, which are promoter methylated in one of the three subtypes. The lncRNA,
 431 *PVT1* was reported for its MYC activity (64,65) and as oncogenic lncRNA with multiple
 432 roles in cell growth, dysfunction, and differentiation in AML (66). Both lncRNAs,
 433 *LINC00312* and *TCL6* have been extensively investigated on expression levels but not on the
 434 epigenetic level. The promoters of both *TCL6* and *LINC00312* were observed to be hyper-
 435 methylated with corresponding diminished expression in the DUX4 and NH-HeH samples.
 436 Notably, the DNA methylation analysis of lncRNAs revealed that DNA methylation might
 437 underlie the differential expression of subtype-specific lncRNAs. Our analysis identified 23
 438 subtype-specific lncRNAs showing hypo-methylation and hyper-methylation pattern at their
 439 promoter region that are significantly correlated with their diminished and increased
 440 expression in respective subtypes. In addition to that, we have identified 33 epigenetically
 441 co-regulated oncogenes localized in the *cis* regions of hypo-methylated and hyper-
 442 methylated lncRNAs from three subtypes. Interestingly, the oncogene associated with
 443 leukemia, IGF2 (44) has shown an elevated expression level in Ph-like subtypes
 444 corresponding to the hypo-methylation of its antisense, IGF2-AS1. These findings suggest
 445 that epigenetic silencing of lncRNAs genes may be a mechanism that contributes to the
 446 dysregulation of expression of lncRNAs and their *cis* genes in BCP-ALL subtypes.

447 Overall, our study provides an in-depth analysis of the lncRNA transcriptome and
 448 epigenome in BCP-ALL subtypes and provides numerous new lncRNAs markers associated
 449 with subtype and relapse-specificity and with epigenetic alterations in BCP-ALL subtypes.
 450 Additionally, we also demonstrated these lncRNAs might contribute to the regulation of key
 451 signalling pathways involved in BCP-ALL. In summary, our study provides a comprehensive
 452 set of dysregulated lncRNAs from BCP-ALL subtypes derived using different integrative
 453 approaches. This can serve as a major resource of BCP-ALL subtype-specific lncRNAs and

their mechanisms of action in detail that might pave the way for the future studies to investigate key biomarkers and potential therapeutic targets in BCP-ALL subtypes.

Materials and Methods

Patient samples

Patients (n = 46) used in this project were negatively selected for fusion genes detectable by routine diagnostic workup (BCR-ABL, MLL translocations, ETV6-RUNX1) from 26 pediatric and 22 adult patients. From these patients we collected 44 samples at initial diagnosis (ID) and 44 samples with relapse (REL). All patients were treated in population-based German study trials (GMALL for adult and BFM for pediatric patients). A written informed consent to participate in these trials according to the Declaration of Helsinki was obtained from all patients. The studies were approved by the ethics board of Charité, Berlin.

Overview of RNA-seq and DNA methylation array data

To generate transcriptome profiles of patient samples, mRNA was isolated by using Trizol reagent (Life Technologies, Grand Island, NY) procedure from the bone marrow mononuclear cells (MNCs) of the ID and REL samples. The paired-end RNA sequencing was done on Illumina HiSeq4000 platform (multiplexing) in the high throughput sequencing core facility, German Cancer Research Center, Heidelberg, Germany. The RNA-Seq was performed by using six samples per lane, which resulted in an average of 64 Million mapped paired reads per sample. For methylation, genomic DNA was isolated using unstranded Allprep extraction (Qiagen, Hilden, Germany) from the bone marrow of same patients (ID and REL samples) was then hybridized onto an Illumina Infinium HumanMethylation450K. From the DNA methylation chip we identified 60,021 probes annotated to 7,190 lncRNAs.

478 **RNA-seq read alignment and quantitative extraction**

479 The STAR aligner (version 2.4.0.1) (67) (2-pass alignment parameters) was used to align
480 paired-end reads to the human genome reference. The human genome reference files used
481 for processing RNA-seq samples were the hg19 (GRCh37) genome version for alignment
482 and transcript annotation from GENCODE version 19 (equivalent Ensembl GRCh37). The
483 transcriptome construction and gene-level counts for each sample were obtained using
484 StringTie (68). The read count information from the files generated by StringTie was
485 extracted using the “prepDE.py” python script provided by the StringTie. We detected 84%
486 of 13,860 lncRNAs (including 23,898 transcripts) annotated by GENCODE (V19) from our
487 samples (FPKM > 0 for multi-exon lncRNAs and FPKM > 0 for single exonic lncRNAs)
488 showing that our sequencing depth was good.

489 **Sample clustering and differential expression analysis for subtype- specific and** 490 **relapse-specific lncRNAs**

491 We performed PCA using the *prcomp* R function on 13,860 lncRNAs from RNA-seq and
492 60,021 CpG's on lncRNAs from DNA methylation datasets. The PCA plots were plotted
493 using python matplotlib axes3D function. The R bioconductor package Linear Models for
494 Microarray (*LIMMA*) *Voom* (69) was used on gene-level expression data for identifying the
495 subtype-specific and relapse-specific differentially expressed (DE) lncRNAs. The subtype-
496 specific DE lncRNAs were identified by implementing separate design matrix for the three
497 subtypes (DUX4, Ph-like and NH-HeH). Within each subtype, we used using all subtype
498 samples versus the rest of the cohort. Within our cohort (82 samples from 46 patients), not
499 all patients had matching ID and REL samples, and moreover, we wanted to compare across
500 subtypes. LIMMA voom leveraged the sample imbalances and confounder (patient and
501 samples) with its *duplicatecorrelation* function. We implemented *duplicatecorrelation*

function which addressed all patient effects by estimating correlations of multiple samples from the same patient while allowing us to compare across the subtypes. Additionally, we included the ID and REL time factors into the design (*makeContrasts*) to avoid the inflation of the variance due to time factor for each subtype. The relapse-specific DE lncRNAs within each subtype were identified by analysing DE lncRNAs ID versus REL samples within each subtype separately. The significant DE genes were assigned based on the p-value < 0.01 and Fold change of $\geq \pm 1.5$. The lncRNAs from GENCODE version 19 (equivalent Ensembl GRCh37) were used as reference annotation. The heatmaps and correlation based (Spearman method) hierarchical clustering of DE lncRNAs were performed on z-score transformed LIMMA normalized gene expression values using the R Bioconductor package ComplexHeatmap.

513 **Differential methylation data analysis**

The ID and REL samples from the same patients have been assayed with the Illumina 450k methylation array. All the beta values have been normalized using the Subset-quantile Within Array Normalization (SWAN) method. In order to detect differentially methylated regions, we used the R package bump hunter (70) using the most variant quartile of the CpG probes. Bump hunter searches for differentially methylated regions in an annotation-unbiased manner. Separate bump hunter runs have been performed for ID and REL samples for every three subtypes (DUX4, Ph-like, and NH-HeH), using all subtype samples versus the rest of the cohort. We associated the differentially methylated regions from three BCP-ALL subtypes using HOMER (hypergeometric optimization of motif enrichment) suite of tool with the reference file GRCh37.74, using the -gene parameter. HOMER provided us with annotation of each probe, we separated lncRNAs from the output. The genomic regions were divided into promoter (± 2 kb from transcription start site, TSS) and gene

body. The gene body was defined if the CpGs were annotated in exonic, intronic or transcription termination site (TTS). The regions mapped to lncRNAs were then used for analysis. The significantly differentially hyper-methylated (Methylation difference value ≥ 0.2 ; P -value ≤ 0.05) and hypo-methylated (Methylation difference value ≤ 0 ; P -value ≤ 0.05) regions were used for further analysis. The intronic and intergenic differentially methylated (DM) lncRNAs were then mapped using 'BedTools' with the B-lymphocyte cell line "wgEncodeBroadHmmGm12878HMM.bed" in order to find the epigenetic markers. The significance of enrichment was calculated using Fisher's exact test. The epigenetically altered lncRNAs were assigned if promoter methylated lncRNAs were differentially expressed and their DNA methylation values (log-transformed Beta values) and expression values (log-transformed FPKM values) are correlated. The most significant correlations (Pearson correlations coefficient, 2-tailed P -value ≤ 0.05) were classified later called as epigenetically altered lncRNAs.

539 **Functional predictions using guilt-by-association approach**

In our study, we used the "guilt-by-association" (71) approach by establishing the pairwise expression correlations between DE lncRNAs (from all BCP-ALL subtypes) and its *cis* and *trans* protein-coding (PC) genes to predict the functions of subtype-specific lncRNAs. We located the *cis* and *trans* PC genes of DE lncRNAs using the GREAT tool (version v3.0.0) (72). All PC genes from GENCODE v19 annotation ($n = 20698$) were used in the analysis. The individual *cis* and *trans* genes for each DE lncRNAs were located within a genomic window of 100 kb and greater >100 kb respectively. From each dataset, we then computed the pairwise expression correlation using Pearson correlation method between each lncRNAs and its *cis* and *trans* coding gene. The significantly co-expressed PC genes (Pearson correlation coefficient ≥ 0.55 and 2-tailed P -value ≤ 0.05) were further used for

functional enrichment analysis using GeneSCF v1.0 (73). The functional enrichment analysis was performed using the KEGG database with a background of all protein-coding genes from GENCODE v19 (20,345). The functional terms were considered significant only if it is enriched with P -value ≤ 0.05 .

ACKNOWLEDGEMENT

We are grateful to Johanna Angermaier for discussions and Ulf Leser for the suggestions in data analysis.

Author Contributions

The project was conceived and designed by: ARJ, CDB, MN, AA. ARJ developed bioinformatics pipeline and analyzed RNA-seq data. MN normalized the methylation data. MSP performed DNA methylation data analysis. MPS, LB, MN and CDB performed the analyses of clinical and molecular data. JOT, CS and KI performed the sample preparation. CMT, MAR, MB, NG, RKS, AVS, MS, MH, TB, SS, HS, SG, RKS, CE were involved in the sample collection, genetic characterization and provided molecular diagnostic data. All authors were involved in writing and reviewing the manuscript.

565 REFERENCES

- 566 1. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of
567 blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. *Clinical*
568 *Pharmacology: Advances and Applications*. 2013. p. 5–11.
- 569 2. Ito C, Kumagai M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG, et al.
570 Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct
571 biological entity with a marked propensity to undergo apoptosis. *Blood*.
572 1999;93(1):315–20.
- 573 3. Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, et al.
574 Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute
575 lymphoblastic leukemia: a report from the children's cancer group. *Blood*.
576 1999;94(12):4036–45.
- 577 4. Dun KA, Vanhaefen R, Batt TJ, Riley LA, Diano G, Williamson J. BCR-ABL1 gene
578 rearrangement as a subclonal change in ETV6-RUNX1-positive B-cell acute
579 lymphoblastic leukemia. *Blood Adv* [Internet]. 2016 Dec;1(2):132—138. Available
580 from: <http://europepmc.org/articles/PMC5737165>
- 581 5. Lilljebjörn H, Fioretos T. New oncogenic subtypes in pediatric B-cell precursor acute
582 lymphoblastic leukemia. *Blood*. 2017. p. 1395–401.
- 583 6. Mullighan CG. Genomic profiling of B-progenitor acute lymphoblastic leukemia. *Best*
584 *Pract Res Clin Haematol* [Internet]. 2011;24(4):489–503. Available from:
585 <http://linkinghub.elsevier.com/retrieve/pii/S1521692611000843>
- 586 7. Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, Von
587 Palffy S, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in
588 paediatric B-cell precursor acute lymphoblastic leukaemia. *Nat Commun*. 2016;7.
- 589 8. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute
590 lymphoblastic leukemia: A high-risk subtype in adults. *Blood*. 2017;129(5):572–81.
- 591 9. Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic
592 landscape of high hyperdiploid childhood acute lymphoblastic leukemia. *Nat Genet*.
593 2015;47(6):672–6.
- 594 10. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic
595 landscape of hypodiploid acute lymphoblastic leukemia. *Nat Genet*. 2013;45(3):242–
596 52.
- 597 11. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, et al.

- 598 Expression and prognostic impact of lncRNAs in acute myeloid leukemia. *Proc Natl*
599 *Acad Sci U S A* [Internet]. 2014;111(52):18679–84. Available from:
600 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4284555&tool=pmcentrez&rendertype=abstract)
601 [artid=4284555&tool=pmcentrez&rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4284555&tool=pmcentrez&rendertype=abstract)
- 602 12. Chen S, Liang H, Yang H, Zhou K, Xu L, Liu J, et al. Long non-coding RNAs: The
603 novel diagnostic biomarkers for leukemia. *Environmental Toxicology and*
604 *Pharmacology*. 2017. p. 81–6.
- 605 13. Kung JTY, Colognori D, Lee JT. Long noncoding RNAs: Past, present, and future.
606 *Genetics*. 2013;193(3):651–69.
- 607 14. Ward M, McEwan C, Mills JD, Janitz M. Conservation and tissue-specific transcription
608 patterns of long noncoding RNAs. *J Hum Transcr* [Internet]. 2015;1(1):2–9.
609 Available from:
610 <http://www.tandfonline.com/doi/full/10.3109/23324015.2015.1077591>
- 611 15. Wang P, Ning S, Zhang Y, Li R, Ye J, Zhao Z, et al. Identification of lncRNA-
612 associated competing triplets reveals global patterns and prognostic markers for
613 cancer. *Nucleic Acids Res*. 2015;43(7):3478–89.
- 614 16. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs.
615 *Nature*. 2012. p. 339–46.
- 616 17. Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, et al. LncRNA loc285194 is a p53-
617 regulated tumor suppressor. *Nucleic Acids Res*. 2013;41(9):4976–87.
- 618 18. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: A
619 new frontier of translational research. *Oncogene*. 2012. p. 4577–87.
- 620 19. Sati S, Ghosh S, Jain V, Scaria V, Sengupta S. Genome-wide analysis reveals distinct
621 patterns of epigenetic features in long non-coding RNA loci. *Nucleic Acids Res*.
622 2012;40(20):10018–31.
- 623 20. Yoon J-H, Abdelmohsen K, Gorospe M. Posttranscriptional Gene Regulation by Long
624 Noncoding RNA. *J Mol Biol*. 2013;425(19):3723–30.
- 625 21. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the
626 genetics of cancer. *Br J Cancer* [Internet]. 2013;108(12):2419–25. Available from:
627 <http://www.nature.com/doi/10.1038/bjc.2013.233>
- 628 22. Gong J, Liu W, Zhang J, Miao X, Guo A-Y. lncRNASNP: a database of SNPs in
629 lncRNAs and their potential functions in human and mouse. *Nucleic Acids Res*
630 [Internet]. 2015;43(D1):D181–6. Available from:
631 <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gku1000>
- 632 23. Zhang Y-Y, Huang S-H, Zhou H-R, Chen C-J, Tian L-H, Shen J-Z. Role of HOTAIR in

- 633 the diagnosis and prognosis of acute leukemia. *Oncol Rep.* 2016;36(6):3113–22.
- 634 24. Wei S, Wang K. Long noncoding RNAs: pivotal regulators in acute myeloid leukemia.
635 *Exp Hematol Oncol* [Internet]. 2015;5(1):30. Available from:
636 <http://ehonline.biomedcentral.com/articles/10.1186/s40164-016-0059-9>
- 637 25. Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, et al. LncRNA
638 profiling in early-stage chronic lymphocytic leukemia identifies transcriptional
639 fingerprints with relevance in clinical outcome. *Blood Cancer J.* 2016;6(9).
- 640 26. Gioia R, Drouin S, Ouimet M, Caron M, St-Onge P, Richer C, et al. LncRNAs
641 downregulated in childhood acute lymphoblastic leukemia modulate apoptosis, cell
642 migration, and DNA damage response. *Oncotarget* [Internet]. 2017; Available from:
643 <http://www.oncotarget.com/fulltext/20817>
- 644 27. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE
645 v7 catalog of human long noncoding RNAs: Analysis of their gene structure,
646 evolution, and expression. *Genome Res.* 2012;22(9):1775–89.
- 647 28. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, et al. Comprehensive Genomic
648 Characterization of Long Non-coding RNAs across Human Cancers. *Cancer Cell.*
649 2015;28(4):529–40.
- 650 29. Ning S, Zhang J, Wang P, Zhi H, Wang J, Liu Y, et al. Lnc2Cancer: A manually
651 curated database of experimentally supported lncRNAs associated with various
652 human cancers. *Nucleic Acids Res.* 2016;44(D1):D980–5.
- 653 30. Colombo T, Farina L, Macino G, Paci P. PVT1: A rising star among oncogenic long
654 noncoding RNAs. *BioMed Research International.* 2015.
- 655 31. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5
656 regulates apoptosis in prostate cancer cell lines. *Biochim Biophys Acta.*
657 2013;1832(10):1613–23.
- 658 32. Petri A, Dybkær K, Bøgsted M, Thruø CA, Hagedorn PH, Schmitz A, et al. Long
659 noncoding RNA expression during human B-cell development. *PLoS One.*
660 2015;10(9).
- 661 33. Guil S, Esteller M. Cis-acting noncoding RNAs: friends and foes. *Nat Struct Mol Biol*
662 [Internet]. 2012;19(11):1068–75. Available from:
663 <http://www.nature.com/doifinder/10.1038/nsmb.2428>
- 664 34. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. MEG3 long
665 noncoding RNA regulates the TGF- β pathway genes through formation of RNA-DNA
666 triplex structures. *Nat Commun.* 2015;6.
- 667 35. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, et al.

- 668 Kcnq1ot1 Antisense Noncoding RNA Mediates Lineage-Specific Transcriptional
669 Silencing through Chromatin-Level Regulation. *Mol Cell*. 2008;32(2):232–46.
- 670 36. Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuire M, et al. PAN-
671 cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and
672 biomarkers. *Nat Commun*. 2018;9(1).
- 673 37. Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, et al. Differential
674 expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged
675 acute lymphoblastic leukemia patients with distinct secondary lesions. *Cancer Lett*.
676 2017;408:92–101.
- 677 38. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic
678 malignancies. *Blood* [Internet]. 2006;107(12):4589–96. Available from:
679 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1895802&tool=pmcentrez&rendertype=abstract)
680 [artid=1895802&tool=pmcentrez&rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1895802&tool=pmcentrez&rendertype=abstract)
- 681 39. Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan A-S, Prchal-Murphy M, Heller G, et
682 al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
683 *Blood*. 2015. 90-101 p.
- 684 40. Wang Y-Y, Wu Z-Y, Wang G-C, Liu K, Niu X-B, Gu S, et al. LINC00312 inhibits the
685 migration and invasion of bladder cancer cells by targeting miR-197-3p. *Tumor Biol*
686 [Internet]. 2016;37(11):14553–63. Available from:
687 <http://link.springer.com/10.1007/s13277-016-5303-8>
- 688 41. Saitou M, Sugimoto J, Hatakeyama T, Russo G, Isobe M. Identification of the TCL6
689 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia.
690 *Oncogene*. 2000;19:2796–802.
- 691 42. Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z, et al. Decoding critical
692 long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. *Nat*
693 *Commun*. 2017;8(1).
- 694 43. ENCODE Project Consortium AIE of DE in the H. An integrated encyclopedia of DNA
695 elements in the human genome. *Nature*. 2012;489(7414):57–74.
- 696 44. Wu HK, Weksberg R, Minden MD, Squire JA. Loss of imprinting of human insulin-like
697 growth factor II gene, IGF2, in acute myeloid leukemia. *Biochem Biophys Res*
698 *Commun*. 1997;231(2):466–72.
- 699 45. Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, et al. Targeting connective
700 tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models:
701 Anti-CTGF monoclonal antibody attenuates leukemia growth. *Ann Hematol*.
702 2014;93(3):485–92.
- 703 46. Fu L, Fu H, Wu Q, Pang Y, Xu K, Zhou L, et al. High expression of ETS2 predicts poor

- 704 prognosis in acute myeloid leukemia and may guide treatment decisions. *J Transl*
705 *Med.* 2017;15(1).
- 706 47. Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohée S, et al.
707 Portraying breast cancers with long noncoding RNAs. *Sci Adv* [Internet].
708 2016;2(9):e1600220. Available from:
709 <http://www.ncbi.nlm.nih.gov/pubmed/27617288>
710 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5010371>
- 711 48. Zhao W, Luo J, Jiao S. Comprehensive characterization of cancer subtype associated
712 long non-coding RNAs and their clinical implications. *Sci Rep* [Internet].
713 2014;4:6591. Available from: [http://www.pubmedcentral.nih.gov/articlerender.fcgi?](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4194441&tool=pmcentrez&rendertype=abstract)
714 [artid=4194441&tool=pmcentrez&rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4194441&tool=pmcentrez&rendertype=abstract)
- 715 49. Chen H, Xu J, Hong J, Tang R, Zhang X, Fang JY. Long noncoding RNA profiles
716 identify five distinct molecular subtypes of colorectal cancer with clinical relevance.
717 *Mol Oncol.* 2014;8(8):1393–403.
- 718 50. Zhou M, Guo M, He D, Wang X, Cui Y, Yang H, et al. A potential signature of eight
719 long non-coding RNAs predicts survival in patients with non-small cell lung cancer. *J*
720 *Transl Med* [Internet]. 2015;13(1):231. Available from: [http://www.translational-](http://www.translational-medicine.com/content/13/1/231)
721 [medicine.com/content/13/1/231](http://www.translational-medicine.com/content/13/1/231)
- 722 51. Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M, et al. Amino acid transporter SLC38A3
723 promotes metastasis of non-small cell lung cancer cells by activating PDK1. *Cancer*
724 *Lett.* 2017;393:8–15.
- 725 52. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: A comprehensive update on its
726 genomics, genetics, functions and increasingly important and numerous roles in
727 health and disease. *Cell Death Differ* [Internet]. Nature Publishing Group;
728 2013;20(12):1603–14. Available from: <http://dx.doi.org/10.1038/cdd.2013.125>
- 729 53. Zhong L, Lou G, Zhou X, Qin Y, Liu L, Jiang W. A six-long non-coding RNAs signature
730 as a potential prognostic marker for survival prediction of ER-positive breast cancer
731 patients. *Oncotarget.* 2017;8(40):3762–72.
- 732 54. Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in
733 osteosarcoma via miR-200c/ABCB1 axis. *Biochem Biophys Res Commun* [Internet].
734 Elsevier Ltd; 2018;495(1):947–53. Available from:
735 <https://doi.org/10.1016/j.bbrc.2017.11.121>
- 736 55. Wang Y, Li Y, Yang Z, Liu K, Wang D. Genome-wide microarray analysis of long non-
737 coding RNAs in Eutopic secretory endometrium with endometriosis. *Cell Physiol*
738 *Biochem.* 2015;37(6):2231–45.
- 739 56. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, et al. Requirement

- 740 for CDK6 in MLL-rearranged acute myeloid leukemia. *Blood*. 2014;124(1):13–23.
- 741 57. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, et al. Pan-Cancer
742 Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each
743 Tumor Context. *Cell Rep*. 2018;23(1):297–312.e12.
- 744 58. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. MEG3 long
745 noncoding RNA regulates the TGF- β pathway genes through formation of RNA-DNA
746 triplex structures. *Nat Commun* [Internet]. 2015;6:7743. Available from:
747 [http://www.nature.com/ncomms/2015/150724/ncomms8743/full/ncomms8743.ht](http://www.nature.com/ncomms/2015/150724/ncomms8743/full/ncomms8743.html)
748 [ml](http://www.nature.com/ncomms/2015/150724/ncomms8743/full/ncomms8743.html)
749 <http://www.nature.com/doi/10.1038/ncomms8743>
750 <http://www.ncbi.nlm.nih.gov/pubmed/26205790>
- 751 59. Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, et al. Targeting
752 the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia
753 and its therapeutic potential. *Leukemia*. 2014;28(4):739–48.
- 754 60. Hui Z, Xianglin M, Access O. Association of HOTAIR expression with PI3K / Akt
755 pathway activation in adenocarcinoma of esophagogastric junction. 2016;36–40.
- 756 61. Feng N, Ching T, Wang Y, Liu B, Lin H, Shi O, et al. Analysis of microarray data on
757 gene expression and methylation to identify long non-coding RNAs in non-small cell
758 lung cancer. *Sci Rep*. 2016;6.
- 759 62. Askarian-Amiri ME, Seyfoddin V, Smart CE, Wang J, Kim JE, Hansji H, et al.
760 Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer.
761 *PLoS One*. 2014;9(7).
- 762 63. Zhang W, Huang C, Gong Z, Zhao Y, Tang K, Li X, et al. Expression of LINC00312, a
763 long intergenic non-coding RNA, is negatively correlated with tumor size but
764 positively correlated with lymph node metastasis in nasopharyngeal carcinoma. *J Mol*
765 *Histol*. 2013;44(5):545–54.
- 766 64. Li JR, Sun CH, Li W, Chao RF, Huang CC, Zhou XJ, et al. Cancer RNA-Seq Nexus: A
767 database of phenotype-specific transcriptome profiling in cancer cells. *Nucleic Acids*
768 *Res*. 2016;44(D1):D944–51.
- 769 65. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1
770 dependence in cancer with MYC copy-number increase. *Nature*. 2014;512(1):82–6.
- 771 66. L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, et al. MYC-
772 containing amplicons in acute myeloid leukemia: genomic structures, evolution, and
773 transcriptional consequences. *Leukemia*. 2018;1–15.
- 774 67. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast
775 universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15–21.

- 776 68. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie
777 enables improved reconstruction of a transcriptome from RNA-seq reads. *Nat*
778 *Biotechnol.* 2015;33(3):290–5.
- 779 69. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential
780 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.*
781 2015;43(7):e47.
- 782 70. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting
783 to identify differentially methylated regions in epigenetic epidemiology studies. *Int J*
784 *Epidemiol.* 2012;41(1):200–9.
- 785 71. Guo X, Gao L, Liao Q, Xiao H, Ma X, Yang X, et al. Long non-coding RNAs function
786 annotation: A global prediction method based on bi-colored networks. *Nucleic Acids*
787 *Res.* 2013;41(2).
- 788 72. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT
789 improves functional interpretation of cis-regulatory regions. *Nat Biotechnol.*
790 2010;28(5):495–501.
- 791 73. Subhash S, Kanduri C. GeneSCF: A real-time based functional enrichment tool with
792 support for multiple organisms. *BMC Bioinformatics.* 2016;17(1).

793

794 **Supporting Information caption**

795 **Fig S1: The distribution of lncRNAs and PC gene expression and DNA methylation**

796 **levels across samples.** (A) The level of distribution of expression between 13460 lncRNAs
797 and 20,135 PC genes across 82 BCP-ALL samples. (B) The level of distribution of DNA
798 methylation rate between 60,022 CpGs probes associated with lncRNAs region and 120,000
799 CpGs probes associated with PC genes across 82 BCP-ALL samples.

800 **Fig S2: BCP-ALL subtype-specific differentially expressed lncRNAs.** (A-C) The

801 hierarchical clustering representing lncRNAs clustering and expression differences of the
802 compared subtypes DUX4, Ph-like and NH-HeH; corresponding to 736, 383, and 445
803 subtype-specific DE lncRNAs in DUX4, Ph-like and NH-HeH subtypes, respectively. In the
804 DUX4 subtype, 100% of samples clustered together based on the DE lncRNAs signature.
805 The hierarchical clustering of the subtype-specific DE lncRNAs revealed that 90% (19 out of
806 21 samples) of Ph-like samples clustered within the predefined Ph-like subtype. For the NH-
807 HeH subtype 69% (11 out of 16 samples) of samples correlated and clustered together
808 using the respective DE lncRNA signature. The BCP-ALL samples box representing the
809 number of samples within each subtypes and versus (vs) the other samples used as control
810 group in DE analysis. (D) The overlap between DE subtype specific lncRNAs from three
811 subtypes versus public list of dysregulated lncRNAs from 12 different cancer types
812 comprehensive cancer genome (CGC)

813 **Fig S3: Comparison of molecular pathways from cis and trans based analysis on**

814 **subtype-specific DE lncRNAs.** (A) Molecular pathway analysis from functional enrichment
815 analysis on *trans* (≥ 100 kb) protein-coding genes correlated (Pearson correlation
816 coefficient ≥ 0.55 and two-tailed P -value ≤ 0.05) with DE lncRNAs in DUX4 subtype.

817 (B) The molecular pathways overlapped between *cis* (< 100 kb proximity) and *trans* (>
818 100 kb) based functional enrichment analysis in the DUX4 subtype. (C) Molecular pathway
819 analysis from functional enrichment analysis on *trans* (> 100 kb) protein-coding genes
820 correlated (Pearson correlation coefficient ≥ 0.55 and two-tailed *P*-value ≤ 0.05) with
821 DE lncRNAs in Ph-like subtype. CAMs : Cell adhesion molecules, CML: Chronic myeloid
822 leukemia , AML: Acute myeloid leukemia.

823 **Fig S4: The subtype-specific lncRNAs co-expressed with oncogenes involved in key**
824 **signaling pathways in DUX4 and Ph-like subtypes.** (A-B) Antisense *RP11-224019.2*
825 (absolute Fold change = 2.786, *P*-value = 9.74E-08) and its *cis* oncogene *TGFB2* (absolute
826 Fold change = 3.84, *P*-value = 2.74E-10) are significantly up-regulated in DUX4 samples.
827 (C) Antisense lncRNAs *R11-536K7.5* located at *cis* region of oncogene *IL2RA*. Expression of
828 antisense lncRNA *RP11-536K7.5* showed significant co-expression with expression of its *cis*
829 oncogene *IL2RA*. Both *RP11-536K7.5* (absolute Fold change = 2.79, *P*-value = 3.07E-008)
830 and *IL2RA* (absolute Fold change = 3.11, *P*-value = 3.97e-1) are up-regulated in Ph-like
831 samples. (D) The expression of *cis* antisense lncRNA *AC002454.1* significant co-expressed
832 with its *cis* oncogene *CDK6* in Ph-like subtype. Both *CDK6* (absolute Fold change = 1.01, *P*-
833 value = 0.0005) and antisense lncRNA *AC002454.1* (absolute Fold change = 1.79, *P*-value
834 = 0.00015) are up-regulated in Ph-like samples.

835 **Table S1. RNA-seq data used for analysis and subtype-specific lncRNAs from three**
836 **subtypes**

837 **Table S2. The functionally involved subtype-specific lncRNAs from DUX4 and Ph-like**
838 **subtypes. The trans and cis-acting subtype-specific lncRNAs**

839 **Table S3. The relapse-specific lncRNAs from three subtypes. The lncRNAs involved in**
840 **functions from DUX4 subtype**

841 **Table S4. DNA methylation array dataset. The differentially methylated lncRNAs from**
 842 **three subtypes. List of cis-acting epigenetically active lncRNAs.**

843 **Figure captions**

844 **Fig 1: BCP-ALL subtype-specific lncRNA expression signatures.**

845 (A) PCA plot constructed from expression FPKM values of lncRNAs from 82 BCP-ALL
 846 samples obtained from RNA-seq. Each point represents a BCP-ALL sample. DUX4, Ph-like,
 847 NH-HeH, LH subtype and others are represented by orange, rose, blue, green and gray
 848 respectively. (B) Heatmap illustrates hierarchical clustering DE subtype-specific lncRNAs
 849 (absolute Fold change $\geq \pm 1.5$, P -value ≤ 0.01) signature based on z-score
 850 transformed LIMMA normalized expression values on 930 subtype-specific lncRNAs from
 851 DUX4 ($n = 450$), Ph-like ($n = 193$), and NH-HeH ($n = 287$) subtypes. (C) The venn
 852 diagram illustrates the overlap between subtype-specific lncRNAs from three subtypes,
 853 showing 24 lncRNAs are to be common for all three subtypes.

854 **Fig 2: The molecular pathways of lncRNAs involved in the DUX4 and Ph-like BCP-ALL**
 855 **subgroups.**

856 (A) The plot depicts the molecular pathway analysis from the functional enrichment
 857 analysis for nearby (≤ 100 kb proximity) cis protein-coding genes correlated (Pearson
 858 correlation coefficient ≥ 0.55 and 2-tailed P -value ≤ 0.05) with DE lncRNAs in the
 859 DUX4 subtype. (B) The plot depicts the molecular pathway analysis from the functional
 860 enrichment analysis for nearby (≤ 100 kb proximity) cis protein-coding genes correlated
 861 (Pearson correlation coefficient ≥ 0.55 and 2-tailed P -value ≤ 0.05) with DE lncRNAs
 862 in the Ph-like subtype. (C) The heatmap depicts the concordance between the protein-
 863 coding and lncRNAs based predictions for DUX4 subtypes. (D) The heatmap depicts the
 864 overlapping pathways from both lncRNAs and protein-coding in the Ph-like subtype. The

KEGG pathways or biological functions presented in the heatmaps and barplots show with P -value ≤ 0.05 and > 2 genes involved in each pathways. The hypergeometric p -values are obtained from GeneSCF for the pathways. CAMs : Cell adhesion molecules, CML : Chronic myeloid leukemia, AML : Acute myeloid leukemia.

Fig 3: Relapse-specific DE lncRNAs from BCP-ALL subtypes.

(A-C) Heatmap depicting the hierarchical clustering on relapse-specific DE lncRNAs signature on Z-score transformed LIMMA normalized expression values from DUX4, Ph-like and NH-HeH subtypes. Each heatmap shows the up and down regulated lncRNAs specific to ID and REL samples. (D) Molecular pathway analysis with the number of genes involved in each pathway from the enrichment analysis of the nearby (< 100 kb proximity) cis protein-coding genes correlated (Pearson correlation > 0.55 and P -value ≤ 0.05) with relapse-specific DE lncRNAs in the DUX4 subtype. The legend box indicates the number of ID and REL samples within each group. CAMs : Cell adhesion molecules. (E) The overlap between relapse-specific and subtype-specific lncRNAs from three subtypes.

Fig 4: Hierarchical clustering of CGID's associated with DM lncRNAs.

(A) PCA of CpG's associated with lncRNAs on SWAN normalized β values on 82 BCP-ALL samples obtained from DNA methylation array. Each point represents a BCP-ALL sample. DUX4, Ph-like, NH-HeH, LH and others are represented by orange, rose, blue, green and gray, respectively. (B) The heatmap representing hierarchal clustering on 544 differentially methylated (DM) CGID's associated with 434 lncRNAs in DUX4 subtype. In the DUX4 subtype, we identified 328 (76%) differentially hypo-methylated and 106 (25%) hyper-methylated lncRNAs. (C) The heatmap representing hierarchal clustering on 518 DM CGID's associated with 450 lncRNAs in the Ph-like subtype. In Ph-like subtype, we observed 302 (67%) hyper-methylated lncRNAs and 148 (33%) hypo-methylated lncRNAs. (D) The

889 heatmap representing hierarchal clustering on 295 DM CGID's associated with 234 lncRNAs
 890 in NH-HeH subtype. In the NH-HeH subtype, we identified 200 (86%) hypo-methylated
 891 and 34 (14%) hyper-methylated lncRNAs. The heatmap is plotted using SWAN normalized
 892 beta values. The barplots below each heatmap represents the distribution of DM lncRNAs in
 893 the genome (Promoter-TSS and gene body) lncRNAs from each subtype. The distribution
 894 DM Promoter-TSS lncRNAs are as follows: 25%, 29% and 39% in DUX4, Ph-like, and NH-
 895 HeH subtype, respectively.

896 **Fig 5: The epigenetically altered promoter methylated lncRNAs and their expression.**

897 (A) The promoter methylated lncRNAs with significant negative correlation with DE
 898 expression profile from the DUX4 subtypes. (B-C) Two representative examples of hypo-
 899 methylated lncRNAs with increased expression profile from DUX4 subtype. lncRNAs, *RP11-*
 900 *138M12.1* (Pearson correlation coefficient = -0.69, 2-tailed *P*-value = 5.21e-13), *RP11-*
 901 *624MB.1* (Pearson correlation coefficient = -0.50, *P*-value = 1.36e-06) are examples with
 902 hypo-methylation and up-regulated expression pattern with significant inverse correlation
 903 between DNA methylation and expression levels. (D) The promoter methylated lncRNAs
 904 with significant negative correlation with DE expression profile from the Ph-like subtypes.
 905 (E) A representative example of the promoter hyper-methylated lncRNA, *RP11-138M12.1*
 906 (Pearson correlation coefficient = -0.69, 2-tailed *P*-value = 5.21e-13) with down-regulated
 907 expression pattern, and with inverse correlation within the Ph-like subtype.

908 **Fig 6: Differentially methylated lncRNAs epigenetically altered expression levels of the**
 909 ***cis* oncogenes.**

910 (A) The upper panel of boxplot represents the DNA methylated lncRNAs, the boxplot
 911 below that represents their corresponding *cis* ocogenes which are up-regulated in DUX4

912 subtype. The barplot shows representative examples of hypo-methylated lncRNAs, *RP11-*
913 *80H8.4* (DNA methylation value = -4.87 , *P*-value = 0.0001), *IGF-AS2* (DNA methylation
914 value = -1.52, *P*-value = 0.011), *RP11-332H18.4* (DNA methylation value = 1.79 , *P*-value
915 = 0.0057), *RGMB-AS1* (DNA methylation value = -1.47, *P*-value = 0.007), and *RP11-*
916 *125B21.2* (DNA methylation value = -1.75, *P*-value = 0.007) and its corresponding
917 significantly up-regulated *cis* oncogenes, *CHT2* (absolute log fold change = 5.021, FDR =
918 2.39E-08), *IGF2* (absolute log fold change = 6.71, FDR = 41.412E-15), *TBX* (absolute log
919 fold change = 5.64, FDR = 3.97E-13), and *RGMB* (absolute log fold change = 4.42, FDR =
920 3.02E-16) within DUX4 subtype. (B) The upper panel of boxplot represents the DNA
921 methylated lncRNAs, the boxplot below that represents their corresponding *cis* ocogenes
922 which are up-regulated in Ph-like subtype. The barplot shows representative examples of
923 hypo-methylated lncRNAs, *RP11-69l8.3* (DNA methylation value= -3.16, *P*-value = 4.46E-
924 08), *LINC00996* (DNA methylation value = -1.55, *P*-value = 0.02), *CTB-79E8.2* (DNA
925 methylation value = -2.22, *P*-value = 0.009), *RP11-420G6.4* (DNA methylation value =
926 -2.43, *P*-value = 0.004) and its corresponding significantly up-regulated *cis* oncogenes,
927 *CTGF* (absolute log fold change = 1.85, = 0.02), *GIMAP8* (absolute log fold change =
928 1.14, FDR = 0.004), *NEURLB* (absolute log fold change = 1.14, FDR = 0.09), *SERPINB1*
929 (absolute log fold change = 1.63, FDR = 0.0004) within Ph-like subtype. (C) The upper
930 panel of boxplot represents the DNA methylated lncRNAs, the boxplot below that
931 represents their *cis* ocogenes which are up-regulated in NH-HeH subtype. The barplot
932 shows representative examples of hypo-methylated lncRNAs, *LINC00114* (DNA methylation
933 value = -2.97, *P*-value = 0.0003), *RP11-293A21.1* (DNA methylation value = -3.69, *P*-
934 value = 0.00071) and its corresponding significantly up-regulated *cis* oncogenes, *ETS2*
935 (absolute Fold change = 0.99, FDR = 0.019) and *STIM2* (absolute Fold change = 2.48,

936 FDR = 6.42E-10) within NH-HeH subtype. False discovery rate: FDR

937 **AVAILABILITY OF DATA AND ACCESSION NUMBERS**


938 All sequencing data used in this study is available at the European Genome
939 phenome Archive (accession number to be provided after acceptance of the manuscript)

940 **FUNDING**


941 This work was supported by the German Cancer Aid (Deutsche Krebshilfe) [grant number
942 111533].

A


bioRxiv preprint first posted online Jul. 9, 2018; doi: <http://dx.doi.org/10.1101/365429>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under a [CC-BY 4.0 International license](#).








B




C







bioRxiv preprint first posted online Jul. 9, 2018; doi: [http://dx.doi.org/10.1101/365429](https://doi.org/10.1101/365429). The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under a CC-BY 4.0 International license.




Number of ID and REL samples in each BCP-ALL subtype

Ph-like	DUX4	NH-HeH
ID (n=10)	ID (n=12)	ID (n=7)
REL (n=11)	REL (n=11)	REL (n=9)




D









Pathways enriched based on relapse specific DUX4 lncRNAs




E

Relapse-specific lncRNAs (867) Subtype-specific lncRNAs (1235)







Exon Intergenic Intron Promoter-TSS TTS





● Hypermethylation & downregulation in subtypes

● Hypomethylation & upregulation in subtypes



▼ DUX4 (n=23) ● Others (n=59)



▼ Ph-like (n=21)
● Others (n=61)

